JP7099672B2 - 医薬化合物 - Google Patents
医薬化合物 Download PDFInfo
- Publication number
- JP7099672B2 JP7099672B2 JP2020501850A JP2020501850A JP7099672B2 JP 7099672 B2 JP7099672 B2 JP 7099672B2 JP 2020501850 A JP2020501850 A JP 2020501850A JP 2020501850 A JP2020501850 A JP 2020501850A JP 7099672 B2 JP7099672 B2 JP 7099672B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- halo
- compound according
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1704714.3 | 2017-03-24 | ||
| GBGB1704714.3A GB201704714D0 (en) | 2017-03-24 | 2017-03-24 | Pharmaceutical compounds |
| PCT/GB2018/000047 WO2018172727A1 (en) | 2017-03-24 | 2018-03-26 | Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020515636A JP2020515636A (ja) | 2020-05-28 |
| JP2020515636A5 JP2020515636A5 (enExample) | 2021-04-15 |
| JP7099672B2 true JP7099672B2 (ja) | 2022-07-12 |
Family
ID=58687800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501850A Active JP7099672B2 (ja) | 2017-03-24 | 2018-03-26 | 医薬化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11220483B2 (enExample) |
| EP (1) | EP3601229B1 (enExample) |
| JP (1) | JP7099672B2 (enExample) |
| KR (1) | KR102636166B1 (enExample) |
| CN (1) | CN110891938B (enExample) |
| AU (1) | AU2018238102B2 (enExample) |
| BR (1) | BR112019019868A2 (enExample) |
| CA (1) | CA3057415A1 (enExample) |
| GB (1) | GB201704714D0 (enExample) |
| MX (1) | MX394818B (enExample) |
| WO (1) | WO2018172727A1 (enExample) |
| ZA (1) | ZA201906873B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102708681B1 (ko) | 2018-02-13 | 2024-09-26 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3781556B1 (en) | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN118221646A (zh) | 2018-07-13 | 2024-06-21 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| EP4153589A4 (en) | 2020-05-19 | 2024-06-12 | Kallyope, Inc. | AMPK ACTIVATORS |
| WO2021263039A1 (en) | 2020-06-26 | 2021-12-30 | Kallyope, Inc. | Ampk activators |
| CN114163426B (zh) * | 2020-09-10 | 2024-03-19 | 上海爱博医药科技有限公司 | 苯并含氧杂环类化合物及其医药应用 |
| JP7214053B2 (ja) * | 2020-10-08 | 2023-01-27 | イーライ リリー アンド カンパニー | 糖尿病治療に有用な６－メトキシ－３，４－ジヒドロ－１ｈ－イソキノリン化合物 |
| CN114671827B (zh) * | 2020-12-24 | 2024-09-20 | 杭州百新生物医药科技有限公司 | 邻苯甲酰磺酰亚胺类衍生物及其应用 |
| KR102605163B1 (ko) * | 2021-06-01 | 2023-11-23 | 연세대학교 산학협력단 | 뇌암의 예방 또는 치료용 조성물 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008512375A (ja) | 2004-09-03 | 2008-04-24 | メモリ ファーマセチカル コーポレーション | 精神医学的又は神経学的症候群の治療用のホスホジエステラーゼ１０阻害剤としての４−置換４，６−ジアルコキシ−シンノリン誘導体 |
| WO2008053446A2 (en) | 2006-11-02 | 2008-05-08 | Piramal Life Sciences Limited | Benzoxazepine compounds, their preparation and use |
| JP2009525275A (ja) | 2006-01-30 | 2009-07-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 多環式１，２，３，４−テトラヒドロ−イソキノリン誘導体およびｐｐａｒモジュレーターとしてのそれらを含む組成物 |
| WO2009147990A1 (ja) | 2008-06-02 | 2009-12-10 | 萬有製薬株式会社 | 新規イソオキサゾール誘導体 |
| WO2016105118A2 (ko) | 2014-12-24 | 2016-06-30 | 주식회사 엘지생명과학 | Gpr120 효능제로서의 바이아릴 유도체 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009504759A (ja) | 2005-08-16 | 2009-02-05 | メモリ ファーマセチカル コーポレーション | ホスホジエステラーゼ１０阻害剤 |
| JP2010519258A (ja) * | 2007-02-22 | 2010-06-03 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｇタンパク質共役受容体のモジュレーターとしてのチアゾール誘導体 |
| WO2013019682A1 (en) | 2011-07-29 | 2013-02-07 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| US10100042B2 (en) | 2014-08-08 | 2018-10-16 | Merck Sharp & Dohme Corp. | [5,6]—fused bicyclic antidiabetic compounds |
| EP3177282B1 (en) | 2014-08-08 | 2021-10-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2017201683A1 (en) | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists |
-
2017
- 2017-03-24 GB GBGB1704714.3A patent/GB201704714D0/en not_active Ceased
-
2018
- 2018-03-26 CN CN201880033700.7A patent/CN110891938B/zh active Active
- 2018-03-26 KR KR1020197031368A patent/KR102636166B1/ko active Active
- 2018-03-26 AU AU2018238102A patent/AU2018238102B2/en active Active
- 2018-03-26 WO PCT/GB2018/000047 patent/WO2018172727A1/en not_active Ceased
- 2018-03-26 US US16/496,786 patent/US11220483B2/en active Active
- 2018-03-26 CA CA3057415A patent/CA3057415A1/en active Pending
- 2018-03-26 BR BR112019019868A patent/BR112019019868A2/pt not_active Application Discontinuation
- 2018-03-26 EP EP18715236.8A patent/EP3601229B1/en active Active
- 2018-03-26 MX MX2019011314A patent/MX394818B/es unknown
- 2018-03-26 JP JP2020501850A patent/JP7099672B2/ja active Active
-
2019
- 2019-10-18 ZA ZA2019/06873A patent/ZA201906873B/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008512375A (ja) | 2004-09-03 | 2008-04-24 | メモリ ファーマセチカル コーポレーション | 精神医学的又は神経学的症候群の治療用のホスホジエステラーゼ１０阻害剤としての４−置換４，６−ジアルコキシ−シンノリン誘導体 |
| JP2009525275A (ja) | 2006-01-30 | 2009-07-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 多環式１，２，３，４−テトラヒドロ−イソキノリン誘導体およびｐｐａｒモジュレーターとしてのそれらを含む組成物 |
| WO2008053446A2 (en) | 2006-11-02 | 2008-05-08 | Piramal Life Sciences Limited | Benzoxazepine compounds, their preparation and use |
| WO2009147990A1 (ja) | 2008-06-02 | 2009-12-10 | 萬有製薬株式会社 | 新規イソオキサゾール誘導体 |
| WO2016105118A2 (ko) | 2014-12-24 | 2016-06-30 | 주식회사 엘지생명과학 | Gpr120 효능제로서의 바이아릴 유도체 |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019133659A (ru) | 2021-04-26 |
| AU2018238102A2 (en) | 2019-11-07 |
| CA3057415A1 (en) | 2018-09-27 |
| GB201704714D0 (en) | 2017-05-10 |
| AU2018238102A1 (en) | 2019-10-31 |
| KR20190140936A (ko) | 2019-12-20 |
| US11220483B2 (en) | 2022-01-11 |
| EP3601229B1 (en) | 2024-11-06 |
| AU2018238102B2 (en) | 2021-11-04 |
| ZA201906873B (en) | 2022-03-30 |
| CN110891938A (zh) | 2020-03-17 |
| RU2019133659A3 (enExample) | 2021-07-16 |
| BR112019019868A2 (pt) | 2020-04-22 |
| KR102636166B1 (ko) | 2024-02-13 |
| WO2018172727A1 (en) | 2018-09-27 |
| EP3601229A1 (en) | 2020-02-05 |
| CN110891938B (zh) | 2023-10-31 |
| MX2019011314A (es) | 2020-01-27 |
| US20200317619A1 (en) | 2020-10-08 |
| MX394818B (es) | 2025-03-24 |
| JP2020515636A (ja) | 2020-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7099672B2 (ja) | 医薬化合物 | |
| JP4171700B2 (ja) | 複素環化合物および使用方法 | |
| TWI285641B (en) | Quinoline and quinoxaline compounds | |
| WO2018006795A1 (zh) | 芳香乙炔或芳香乙烯类化合物、其中间体、制备方法、药物组合物及应用 | |
| JP2019529490A (ja) | 嚢胞性線維症膜コンダクタンス制御因子の調節因子、医薬組成物、処置の方法、及び当該調節因子を作製するためのプロセス | |
| CN114258390A (zh) | 用于疾病治疗的乙醇酸氧化酶抑制剂 | |
| JPH11269146A (ja) | 分化誘導剤 | |
| WO2016169504A1 (zh) | 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用 | |
| KR20190034318A (ko) | Ido1억제제 및 이의 제조방법과 응용 | |
| JP7503850B2 (ja) | シャペロン介在性オートファジー調節剤として有用なベンゾオキサゾールおよび関連化合物 | |
| JP2015157836A (ja) | キノロン化合物及び医薬組成物 | |
| US10519138B2 (en) | Modulators of SOCE, compositions, and uses thereof | |
| WO2012173174A1 (ja) | アザスピロアルカン化合物 | |
| JP7262141B2 (ja) | シャペロン介在性オートファジー調節剤として有用な化合物 | |
| TW202225152A (zh) | ２－吡啶酮類衍生物及其製備方法和在醫藥上的應用 | |
| US20130065907A1 (en) | 5-cycloalkyl- or 5-heterocyclyl-nicotinamides | |
| WO2013151877A1 (en) | Pyrimidinedione carboxamide inhibitors of endothelial lipase | |
| JP5769504B2 (ja) | 医薬 | |
| CN113891879A (zh) | 3,6-二取代的-2-吡啶醛肟骨架 | |
| RU2776801C2 (ru) | Производные тетрагидробензо[d]азапена в качестве модуляторов as gpr120 | |
| TW201404772A (zh) | 噁唑烷酮類衍生物、其製備方法及其在醫藥上的應用 | |
| KR20250158047A (ko) | 소르틸린 활성 조절제 | |
| KR20250030474A (ko) | 화합물, 조성물 및 이의 사용 방법 | |
| HK1230186A1 (en) | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210303 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210303 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220113 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220418 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220531 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220616 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7099672 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |